|
1
|
Yao JC, Hassan M, Phan A, Dagohoy C, Leary
C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A and Evans
DB: One hundred years after ‘Carcinoid’: Epidemiology of and
prognostic factors for neuroendocrine tumors in 35,825 cases in the
United States. J Clin Oncol. 26:3063–3072. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yao JC, Eisner MP, Leary C, Dagohoy C,
Phan A, Rashid A, Hassan M and Evans DB: Population-based study of
islet cell carcinoma. Ann Surg Oncol. 14:3492–3500. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fitzgerald TL, Hickner ZJ, Schmitz M and
Kort EJ: Changing incidence of pancreatic neoplasms: A 16-year
review of statewide tumor registry. Pancreas. 37:134–138. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Panzuto F, Boninsegna L, Fazio N, Campana
D, Pia Brizzi M, Capurso G, Scarpa A, De Braud F, Dogliotti L,
Tomassetti P, et al: Metastatic and locally advances pancreatic
endocrine carcinomas: Analysis of factors associated with disease
progression. J Clin Oncol. 29:2372–2377. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Macheda ML, Rogers S and Best JD:
Molecular and cellular regulation of glucose transporter (GLUT)
proteins in cancer. J Cell Physiol. 202:654–662. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Farrell CL, Yang J and Pardridge WM:
GLUT-1 glucose transporter is present within apical and basolateral
membranes of brain epithelial interfaces and in microvascular
endothelia with and without tight junctions. J Histochem Cytochem.
40:193–199. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mueckler M: Facilitative glucose
transporters. Eur J Biochem. 219:713–725. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Clavo AC, Brown RS and Wahl RL:
Fluorodeoxyglucose uptake in human cancer cell lines is increased
by hypoxia. J Nucl Med. 36:1625–1632. 1995.PubMed/NCBI
|
|
9
|
Kang SS, Chun YK, Hur MH, Lee HK, Kim YJ,
Hong SR, Lee JH, Lee SG and Park YK: Clinical significance of
glucose transporter 1 (GLUT1) expression in human breast carcinoma.
Jpn J Cancer Res. 93:1123–1128. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
De Schutter H, Landuyt W, Verbeken E,
Goethals L, Hermans R and Nuyts S: The prognostic value of the
hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in
head and neck squamous cell carcinoma treated by radiotherapy +/-
chemotherapy. BMC Cancer. 5:422005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Reis H, Tschirdewahn S, Szarvas T, Rübben
H, Schmid KW and Grabellus F: Expression of GLUT1 is associated
with increasing grade of malignancy in non-invasive and invasive
urothelial carcinomas of the bladder. Oncol Lett. 2:1149–1153.
2011.PubMed/NCBI
|
|
12
|
Wincewicz A, Sulkowska M, Koda M and
Sulkowski S: Clinicopathological significance and linkage of the
distribution of HIF-1alpha and GLUT-1 in human primary colorectal
cancer. Pathol Oncol Res. 13:15–20. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Younes M, Brown RW, Stephenson M, Gondo M
and Cagle PT: Overexpression of GLUT1 and GLUT3 in stage I nonsmall
cell lung carcinoma is associated with poor survival. Cancer.
80:1046–1051. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ozbudak IH, Shilo K, Tavora F, Rassaei N,
Chu WS, Fukuoka J, Jen J, Travis WD and Franks TJ: Glucose
tranporter-1 in pulmonary neuroendocrine carcinomas: Expression and
survival analysis. Mod Pathol. 22:633–638. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu CH, Ho YS, Tsai CY, Wang YJ, Tseng H,
Wei PL, Lee CH, Liu RS and Lin SY: In vitro and in vivo study of
phloretin-induced apoptosis in human liver cancer cells involving
inhibition of type II glucose transporter. Int J Cancer.
124:2210–2219. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brown RS and Wahl RL: Overexpression of
GLUT-1 glucose transporter in human breast cancer. An
immunohistochemical study. Cancer. 72:2979–2985. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jung JH, Im S, Jung ES and Kang CS:
Clinicopathological implications of the expression of
hypoxia-related proteins in gastric cancer. Int J Med Sci.
10:1217–1223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Semenza GL: Hypoxia, clonal selection and
the role of HIF-1 in tumor progression. Biochm Mol Biol. 35:71–103.
2000.
|
|
19
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Cancer. 3:721–732. 2003.PubMed/NCBI
|
|
20
|
Zhong H, De Marzo AM, Laughner E, Lim M,
Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons
JW: Overexpression of hypoxia-inducible factor 1alpha in common
human cancers and their metastases. Cancer Res. 59:5830–5835.
1999.PubMed/NCBI
|
|
21
|
Mueller-Pillasch F, Pohl B, Wilda M,
Lacher U, Beil M, Wallrapp C, Hameister H, Knöchel W, Adler G and
Gress TM: Expression of the highly conserved RNA binding protein
KOC in embryogenesis. Mech Dev. 88:95–99. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nielsen J, Christiansen J, Lykke-Andersen
J, Johnsen AH, Wewer UM and Nielsen FC: A family of insulin-like
growth factor II mRNA binding proteins represses translation in
late development. Mol Cell Biol. 19:1262–1270. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liao B, Hu Y, Herrick DJ and Brewer G: The
RNA-binding protein IMP-3 is a translational activator of
insulin-like growth factor II leader-3 mRNA during proliferation of
human K562 leukemia cells. J Biol Chem. 280:18517–18524. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu H, Burne PA, Spaulding BO and Wang HL:
High-grade neuroendocrine carcinomas of the lung express K homology
domain containing protein overexpressed in cancer but carcinoid
tumors do not. Hum Pathol. 38:555–563. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Klimstra DS, Arnold R, Capella C, Hruban
RH, Klöppel G, Komminoth P, Solcia E and Rindi G: Neuroendocrine
neoplasms of the pancreas. WHO Classification of Tumors of the
Digestive System. Bosman FT, Carneiro F, Hruban RH and Theise ND:
IARC Press. (Lyon). 322–326. 2010.
|
|
26
|
Frendrich V, Schneider R, Maitra A,
Jacobsen ID, Opfermann T and Bartsch DK: Detection of precursor
lesions of pancreatic adenocarcinoma in PET-CT in a genetically
engineered mouse model or pancreatic cancer. Neoplasisa.
13:180–186. 2011. View Article : Google Scholar
|
|
27
|
Morimatsu K, Aishima S, Yamamoto H,
Hayashi A, Nakata K and Oda Y, Shindo K, Fujino M, Tanaka M and Oda
Y: Insulin-like growth factor II messenger RNA-binding protein-3 is
a valuable diagnostic and prognostic marker of intraductal
papillary mucinous neoplasm. Hum Pathol. 44:1714–1721. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schaeffer DF, Owen DR, Lim HJ, Buczkowski
AK, Chung SW, Scudamore CH, Huntsman DG, Ng SS and Owen DA:
Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3)
overexpression in pancreatic ductal adenocarcinoma correlates with
poor survival. BMC Cancer. 10:592010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wachter DL, Schlabrakowski A, Hoegel J,
Kristiansen G, Hartmann A and Riener MO: Diagnostic value of
immunohistochemical IMP3 expression in core needle biopsies of
pancreatic ductal adenocarinoma. Am J Surg Patol. 35:873–877. 2011.
View Article : Google Scholar
|
|
30
|
Jeng YM, Chang CC, Hu FC, Chou HE, Kao HL,
Wang TH and Hsu HC: RNA-binding protein insulin-like growth factor
II mRNA-binding protein 3 expression promotes tumor invasion and
predicts early recurrence and poor prognosis in hepatocellular
carcinoma. Hepatology. 48:1118–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
